Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference
Dachuan Huang1,2, Wee Wei Tee3,4, Sanjay De Mel5,6
1Lymphoma Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
Cancer Research
|July 2, 2026
Summary
Frontiers in Cancer Science 2025 advanced proactive cancer care by integrating multiomics, computational biology, and genomics. Insights into metabolic vulnerabilities and therapeutic engineering pave the way for personalized, interceptive oncology.
Area of Science:
- Oncology
- Genomics
- Computational Biology
Background:
- The 17th Annual Frontiers in Cancer Science (FCS) conference convened in 2025.
- Cancer research is increasingly focusing on multiomics, computational biology, and genomics for proactive care.
Purpose of the Study:
- To highlight key advancements and insights presented at the FCS 2025 conference.
- To emphasize the integration of diverse scientific disciplines for future cancer management.
Main Methods:
- Discussion of epigenetic plasticity and metabolic vulnerabilities (e.g., WNK1-mTORC1 axis, MAF-driven glutamine metabolism).
- Exploration of systemic cancer biology, including neutrophil priming and spatial immunotherapy barriers.
- Showcasing therapeutic engineering breakthroughs (CAR T cells, KRAS inhibitors) and AI-driven approaches (fragmentomics).
Main Results:
- Identification of key molecular targets and pathways in leukemia and myeloma.
- Understanding of tumor microenvironment interactions and immunotherapy resistance mechanisms.
- Advancements in precision oncology, addressing ancestry-specific genomic disparities through ancestry-aware datasets and long-read sequencing.
Conclusions:
- The future of oncology involves integrating high-resolution disease models with data science.
- A shift towards personalized, interceptive cancer management from reactive treatment is envisioned.
- Multi-disciplinary approaches are crucial for addressing complex cancer biology and improving patient outcomes.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...